A Study of Axatilimab at 3 Different Doses in Patients With Chronic Graft Versus Host Disease (cGVHD)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
AGAVE-201 is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab
at 3 different dose levels in patients with recurrent or refractory active chronic graft
versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy due
to progression of disease, intolerability or toxicity.